Global Tiamulin Fumarate Use in Animal Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Tiamulin Fumarate Use in Animal Market Research Report 2024
Tiamulin hydrogen fumarate is a semisynthetic derivative of pleuromutilin. Tiamulin is active against gram-positive bacteria, mycoplasmas, and anaerobes, including Brachyspira hyodysenteriae. Tiamulin is well absorbed when administered PO. It is labeled for use as an oral medicated feed or water in swine in the US to treat swine dysentery and Actinobacillus pleuropneumoniae. In poultry, tiamulin interferes with monensin and salinomycin metabolism, and if the drugs are administered together, they become toxic. Generally, however, tiamulin has few adverse effects.
According to Mr Accuracy reports’s new survey, global Tiamulin Fumarate Use in Animal market is projected to reach US$ 115.7 million in 2029, increasing from US$ 97.3 million in 2022, with the CAGR of 5.0% during the period of 2024 to 2029.
The Tiamulin Hydrogen Fumarate for Veterinary Market is driven by the increasing demand for effective antibiotics in animal healthcare to combat bacterial infections and improve livestock health. Tiamulin Hydrogen Fumarate is widely used to treat respiratory and enteric diseases in animals. However, a significant challenge in this market is the concern over antibiotic resistance and the need for responsible antibiotic usage. Regulatory restrictions and growing awareness about antibiotic stewardship pose challenges for manufacturers. Additionally, market competition and the cost of antibiotics in veterinary medicine require manufacturers to strike a balance between affordability and quality to ensure the continued availability and effectiveness of Tiamulin Hydrogen Fumarate for veterinary use.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Tiamulin Fumarate Use in Animal market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Sunny Biotech
Hebei Weiyuan
Shandong Shengli
Shandong Lukang
Qingdao Dierman
Qilu Pharma
Huvepharma
Novartis
Vethellas
Elanco
Segment by Type
Premix
API Powder
Livestock
Poultry
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Tiamulin Fumarate Use in Animal report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Tiamulin Fumarate Use in Animal market is projected to reach US$ 115.7 million in 2029, increasing from US$ 97.3 million in 2022, with the CAGR of 5.0% during the period of 2024 to 2029.
The Tiamulin Hydrogen Fumarate for Veterinary Market is driven by the increasing demand for effective antibiotics in animal healthcare to combat bacterial infections and improve livestock health. Tiamulin Hydrogen Fumarate is widely used to treat respiratory and enteric diseases in animals. However, a significant challenge in this market is the concern over antibiotic resistance and the need for responsible antibiotic usage. Regulatory restrictions and growing awareness about antibiotic stewardship pose challenges for manufacturers. Additionally, market competition and the cost of antibiotics in veterinary medicine require manufacturers to strike a balance between affordability and quality to ensure the continued availability and effectiveness of Tiamulin Hydrogen Fumarate for veterinary use.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Tiamulin Fumarate Use in Animal market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Sunny Biotech
Hebei Weiyuan
Shandong Shengli
Shandong Lukang
Qingdao Dierman
Qilu Pharma
Huvepharma
Novartis
Vethellas
Elanco
Segment by Type
Premix
API Powder
Segment by Application
Livestock
Poultry
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Tiamulin Fumarate Use in Animal report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices